Is recurrent venous thromboembolism after therapy reduced by low-molecular-weight heparin compared with oral anticoagulants?

Chest

Volumn 130, Issue 6, 2006, Pages 1808-1816

  Ferretti, Gianluigi ^a   Bria, Emilio ^a   Giannarelli, Diana ^a   Carlini, Paolo ^a   Felici, Alessandra ^a   Mandalà, Mario ^b   Papaldo, Paola ^a   Fabi, Alessandra ^a   Ciccarese, Mariangela ^a   Cuppone, Federica ^a   Cecere, Fabiana Letizia ^a   Nuzzo, Carmen ^a   Terzoli, Edmondo ^a   Cognetti, Francesco ^a  

^a REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^b TREVIGLIO HOSPITAL   (Italy)

Author keywords

Deep vein thrombosis; Low molecular weight heparin; Oral anticoagulant therapy; Venous thromboembolism; Vitamin K antagonists

Indexed keywords

ACENOCOUMAROL; ANTICOAGULANT AGENT; ANTIVITAMIN K; BEMIPARIN; COUMARIN DERIVATIVE; DALTEPARIN; ENOXAPARIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; PHENPROCOUMON; TINZAPARIN; WARFARIN;

ARTICLE; BIBLIOGRAPHIC DATABASE; CLINICAL TRIAL; COCHRANE LIBRARY; CONFIDENCE INTERVAL; DEEP VEIN THROMBOSIS; DRUG EFFECT; DRUG EFFICACY; EVALUATION; HUMAN; LONG TERM CARE; MEDICAL SOCIETY; MEDLINE; META ANALYSIS; OUTCOME ASSESSMENT; OUTCOMES RESEARCH; PRIORITY JOURNAL; RECURRENT DISEASE; RISK FACTOR; SYMPTOM; SYSTEMATIC REVIEW; VENOUS THROMBOEMBOLISM;

EID: 33845959873     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.130.6.1808     Document Type: Article

References (30)

1. Bijsterveld NR, Peters RJ, Murphy SA, et al. Recurrent cardiac ischemic events early after discontinuation of short-term heparin treatment in acute coronary syndromes: results from the Thrombolysis in Myocardial Infarction (TIMI) IIB and Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events (ESSENCE) studies. J Am Coll Cardiol 2003; 42:2083-2089
2. Bijsterveld NR, Moons AH, Meijers JC, et al. Rebound thrombin generation after heparin therapy in unstable angina: a randomized comparison between unfractionated and low-molecular-weight heparin. J Am Coll Cardiol 2002; 39:811-817
3. Heijden JF, Hutten BA, Büller HR, et al. Vitamin K antagonists or low-molecular-weight heparin for the long term treatment of symptomatic venous thromboembolism. The Cochrane Library 2004, Issue 4
4. Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med 1998; 17:2815-2834
5. Takkouche B, Cadarso-Suarez C, Spiegelman D. Evaluation of old and new tests of heterogeneity in epidemiologic meta-analysis. Am J Epidemiol 1999; 150:206-215
6. Bria E, Giannarelli D, Felici A, et al. Taxanes with anthracyclines as first-line chemotherapy for metastatic breast carcinoma: pooled analysis of 2805 patients. Cancer 2005; 103: 672-679
7. Lee AY, Levine MN, Baker RI, et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 2003; 349:146-153
8. Fini M, Aiello S, Manotti C, et al. Low molecular weight heparin versus warfarin in the prevention of recurrences after deep vein thrombosis. Thromb Haemost; 1994; 72:191-197
9. Das SK, Cohen AT, Edmondson RA, et al. Low-molecular-weight heparin versus warfarin for prevention of recurrent venous thromboembolism: a randomized trial. World J Surg 1996; 20:521-526
10. Gonzalez-Fajardo JA, Arreba E, Castrodeza J, et al. Venographic comparison of subcutaneous low-molecular-weight heparin with oral anticoagulant therapy in the long-term treatment of deep venous thrombosis. J Vasc Surg 1999; 30:283-290
11. Lopaciuk S, Bielska-Falda H, Noszczyk W, et al. Low molecular weight heparin versus acenocoumarol in the secondary prophylaxis of deep vein thrombosis. Thromb Haemost 1999; 81:26-31
12. Veiga F, Escriba A, Maluenda MP, et al. Low-molecular weight heparin (enoxaparin) versus oral anticoagulant therapy (acenocoumarol) in the long-term treatment of deep venous thrombosis in the elderly: a randomized trial. Thromb Haemost 2000; 84:559-564
13. Lopez-Beret P, Orgaz A, Fontcuberta J, et al. Low-molecular weight heparin versus oral anticoagulant in the long-term treatment of deep venous thrombosis. J Vasc Surg 2001; 33:77-90
14. Meyer G, Marjanovic Z, Valcke J, et al. Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study. Arch Intern Med 2002; 162:1729-1735
15. Hull RD, Pineo GF, Mah AF, et al, for the LITE Study Investigators. A randomized trial evaluating long-term low-molecular-weight heparin therapy for three months versus intravenous heparin followed by warfarin sodium [abstract]. Blood 2002; 100:148a
16. Kakkar VV, Gebska M, Kadziola Z, et al, Bemiparin Investigators. Low-molecular-weight heparin in the acute and long-term treatment of deep vein thrombosis. Thromb Haemost 2003; 89:674-680
17. Deitcher SR, Kessler MG, Lyons RM. Treatment of venous thromboembolic events (VTE) in patients with active malignancy: a randomized study of enoxaparin alone versus initial enoxaparin followed by warfarin for a 180-day period [abstract]. Blood 2003; 102:322a
18. Moher D, Fortin P, Jadad AR, et al. Completeness of reporting of trials published in languages other than English: implications for conduct and reporting of systematic reviews. Lancet 1996; 347:363-366
19. Hamann H. Low molecular weight heparin versus coumarin in the prevention of recurrence after deep vein thrombosis [in German]. Vasomed 1998; 10:133-136
20. Hamann H. Secondary prevention after deep venous thrombosis: low molecular weight heparin versus coumarin [in German] Zentralbl Chir 1999; 124:24-26
21. Hull RD, Pineo GF, Mah AF, for the LITE Study Investigators. Does rebound exist? A comparison of venous thromboembolic (VTE) event rates in the post-treatment period for patients randomized to long-term low-molecular-weight heparin (LMWH) versus warfarin sodium [abstract]. Blood 2002; 100:501a
22. Iorio A, Guercini F, Pini M. Low-rnolecular-weight heparin for the long-term treatment of symptomatic venous thromboembolism: meta-analysis of the randomized comparisons with oral anticoagulants. J Thromb Haemost 2003; 1:1906-1913
23. Hull R, Pineo G, Mah A, et al. The LITE Investigators: long-term low molecular weight heparin treatment versus oral anticoagulant therapy for proximal deep vein thrombosis [abstract]. Blood 2000; 96:1933
24. Palareti G, Legnani C, Lee A, et al. A comparison of the safety and efficacy of oral anticoagulation for the treatment of venous thromboembolic disease in patients with or without malignancy. Thromb Haemost 2000; 84:805-810
25. Prandoni P, Lensing AW, Piccioli A, et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood 2002; 100:3484-3488
26. Lee AYY, Rickles FR, Julian JA, et al. Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism. J Clin Oncol 2005; 23:2123-2129
27. Ferretti G, Bria E, Giannarelli D, et al. Low-molecular-weight heparin versus oral anticoagulant therapy for the long-term treatment of symptomatic venous thromboembolism: is there any difference in cancer-related mortality? J Clin Oncol 2005; 23:7248-7250
28. Young E, Wells P, Holloway S, et al. Ex-vivo and in-vitro evidence that low molecular weight heparins exhibit less binding to plasma proteins than unfractionated heparin. Thromb Haemost 1994; 71:300-304
29. Hoppensteadt D, Walenga JM, Fareed J. Low molecular weight heparins: an objective overview. Drugs Aging 1992; 2:406-422
30. Dolovich LR, Ginsberg JS, Douketis JD, et al. Meta-analysis comparing low-molecular-weight heparins with unfractionated heparin in the treatment of venous thromboembolism: examining some unanswered questions regarding location of treatment, product type, and dosing frequency. Arch Intern Med 2000; 160:181-188